Glenmark Pharmaceuticals Ltd launches U.S. authorized generic axitinib tablets, 1 mg and 5 mg
- Authorized generic version of INLYTA® (axitinib).
- U.S. INLYTA® tablet sales were approximately $538.4 million for the 12 months ended September 2026, according to IQVIA.
- Glenmark said the launch expands its U.S. portfolio and supports access to affordable treatments.
